Provectus Biopharmaceuticals Inc
OTC:PVCT
Provectus Biopharmaceuticals Inc
OTC:PVCT
Price:
0.0465
USD
3.33%
Market Closed
Market Cap:
$19.5m
Balance Sheet
Balance Sheet Decomposition
Provectus Biopharmaceuticals Inc
Provectus Biopharmaceuticals Inc
Balance Sheet Decomposition is not available for
Provectus Biopharmaceuticals Inc
Provectus Biopharmaceuticals Inc
Balance Sheet
Provectus Biopharmaceuticals Inc
Provectus Biopharmaceuticals Inc
Currency: USD
| Dec-2002 | Dec-2003 | Dec-2004 | Dec-2005 | Dec-2006 | Dec-2007 | Dec-2008 | Dec-2009 | Dec-2010 | Dec-2011 | Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||||||
| Cash & Cash Equivalents |
1
|
0
|
0
|
7
|
1
|
3
|
3
|
3
|
8
|
8
|
1
|
16
|
17
|
14
|
1
|
0
|
0
|
1
|
0
|
1
|
0
|
0
|
0
|
|
| Cash |
1
|
0
|
0
|
7
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash Equivalents |
0
|
0
|
0
|
0
|
0
|
3
|
3
|
3
|
8
|
8
|
1
|
16
|
17
|
14
|
1
|
0
|
0
|
1
|
0
|
1
|
0
|
0
|
0
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
7
|
4
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
2
|
1
|
1
|
|
| Total Current Assets |
1
|
1
|
1
|
7
|
7
|
7
|
3
|
3
|
8
|
8
|
1
|
16
|
19
|
15
|
2
|
1
|
1
|
1
|
0
|
3
|
2
|
1
|
1
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Intangible Assets |
20
|
11
|
10
|
10
|
9
|
8
|
8
|
7
|
6
|
6
|
5
|
4
|
4
|
3
|
2
|
2
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
3
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
21
N/A
|
12
-43%
|
11
-7%
|
17
+55%
|
16
-6%
|
16
-4%
|
11
-33%
|
10
-3%
|
14
+41%
|
13
-7%
|
6
-54%
|
20
+223%
|
26
+31%
|
20
-22%
|
6
-73%
|
3
-39%
|
2
-42%
|
1
-26%
|
1
-60%
|
4
+495%
|
2
-42%
|
1
-29%
|
1
-31%
|
|
| Liabilities | ||||||||||||||||||||||||
| Accounts Payable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
2
|
3
|
3
|
1
|
1
|
1
|
2
|
2
|
1
|
|
| Accrued Liabilities |
0
|
1
|
0
|
2
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
2
|
0
|
1
|
1
|
1
|
6
|
2
|
3
|
3
|
2
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
3
|
|
| Current Portion of Long-Term Debt |
0
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
24
|
2
|
2
|
3
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
2
|
1
|
0
|
|
| Total Current Liabilities |
0
|
2
|
1
|
3
|
1
|
1
|
0
|
1
|
1
|
0
|
1
|
1
|
1
|
4
|
2
|
4
|
4
|
3
|
31
|
8
|
8
|
9
|
7
|
|
| Long-Term Debt |
1
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
9
|
14
|
20
|
0
|
0
|
0
|
0
|
0
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
3
|
1
|
13
|
0
|
0
|
0
|
0
|
1
|
3
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
1
N/A
|
2
+53%
|
2
+13%
|
3
+44%
|
1
-73%
|
1
+10%
|
0
-48%
|
1
+80%
|
4
+346%
|
3
-10%
|
2
-46%
|
13
+639%
|
1
-93%
|
4
+316%
|
2
-48%
|
13
+529%
|
19
+44%
|
26
+32%
|
31
+21%
|
8
-75%
|
8
+7%
|
9
+9%
|
7
-23%
|
|
| Equity | ||||||||||||||||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
7
|
10
|
15
|
26
|
35
|
45
|
55
|
68
|
86
|
106
|
118
|
146
|
156
|
181
|
205
|
219
|
227
|
234
|
240
|
246
|
250
|
253
|
257
|
|
| Additional Paid In Capital |
27
|
20
|
24
|
41
|
51
|
60
|
65
|
77
|
97
|
116
|
123
|
153
|
181
|
197
|
208
|
208
|
209
|
209
|
210
|
241
|
243
|
245
|
251
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
20
N/A
|
10
-49%
|
9
-11%
|
14
+57%
|
16
+8%
|
15
-4%
|
10
-32%
|
9
-6%
|
11
+14%
|
10
-6%
|
4
-56%
|
7
+51%
|
25
+280%
|
16
-35%
|
3
-79%
|
10
N/A
|
17
-74%
|
24
-38%
|
30
-26%
|
4
+86%
|
6
-49%
|
8
-22%
|
6
+22%
|
|
| Total Liabilities & Equity |
21
N/A
|
12
-43%
|
11
-7%
|
17
+55%
|
16
-6%
|
16
-4%
|
11
-33%
|
10
-3%
|
14
+41%
|
13
-7%
|
6
-54%
|
20
+223%
|
26
+31%
|
20
-22%
|
6
-73%
|
3
-39%
|
2
-42%
|
1
-26%
|
1
-60%
|
4
+495%
|
2
-42%
|
1
-29%
|
1
-31%
|
|
| Shares Outstanding | ||||||||||||||||||||||||
| Common Shares Outstanding |
9
|
11
|
16
|
28
|
42
|
49
|
53
|
67
|
91
|
111
|
118
|
160
|
185
|
205
|
365
|
371
|
385
|
390
|
399
|
419
|
420
|
420
|
420
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
4
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
22
|
22
|
23
|
14
|
|
Switch to:
Switch to:
See Also
Discover More
